Gil Blum is ranked #1063 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

NDM

Gil Blum

Q: How accurate are Gil Blum's stock ratings?

About 54% of Gil's ratings were profitable over a one-year hold, with an average return of +8.5% per rating, measured by 13Foresight from historical prices.

Needham

Wall Street Analyst

★★★☆☆

#1063

on 13Foresight · ranked by our own returns

54%

Success Rate

+8.5%

Average Return

33 of 61 calls profitable · +5.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 54% of Gil Blum's ratings turned a profit when each position was held for 1 year — averaging +8.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

146 Buy 23 Hold 9 Sell

Gil's Stock Coverage 28 ratings · 2026-08-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
ABSI AbSci	Aug 12, 2026	BUY	Strong Buy +28.1% avg upside 18 analysts	$11.00 15.85% Upside	+0.5%	·
TCRX TScan Therapeutics	Aug 12, 2026	BUY	Strong Buy +1003.4% avg upside 12 analysts	$6.00 676.12% Upside	+0.0%	·
TSHA Taysha Gene Therapies	Aug 12, 2026	BUY	Strong Buy +116.5% avg upside 21 analysts	$12.00 87.36% Upside	-4.2%	·
MREO Mereo Biopharma Group Plc	Aug 11, 2026	BUY	Strong Buy +1218.3% avg upside 11 analysts	$3.00 890.41% Upside	-3.2%	·
RCKT Rocket Pharmaceuticals	Aug 11, 2026	HOLD	Buy +384.4% avg upside 29 analysts	—	-4.6%	·
NKTX Nkarta	Aug 11, 2026	BUY	Strong Buy +681.8% avg upside 16 analysts	$11.00 360.33% Upside	-1.3%	·
AUTL Autolus Therapeutics	Aug 11, 2026	BUY	Strong Buy +390.7% avg upside 16 analysts	$10.00 371.63% Upside	-9.0%	·
IMMX Immix Biopharma	Aug 10, 2026	BUY	Strong Buy +64.2% avg upside 9 analysts	$21.00 84.77% Upside	+7.8%	·
LYEL Lyell Immunopharma	Aug 07, 2026	BUY	Strong Buy +94.5% avg upside 12 analysts	$44.00 210.52% Upside	-6.6%	·
ARTV Artiva Biotherapeutics, Inc.	Aug 07, 2026	BUY	Strong Buy +159.2% avg upside 7 analysts	$41.00 255.55% Upside	+0.3%	·
SLDB Solid Biosciences	Aug 07, 2026	BUY	Strong Buy +75.2% avg upside 23 analysts	$19.00 109.61% Upside	+7.1%	·
SRPT Sarepta Therapeutics	Aug 06, 2026	SELL	Buy +225.4% avg upside 49 analysts	—	-0.0%	·
RNAC Cartesian Therapeutics	Aug 06, 2026	BUY	Strong Buy +265.0% avg upside 19 analysts	$40.00 361.11% Upside	+1.0%	·
IMCR Immunocore Holdings	Aug 06, 2026	BUY	Strong Buy +85.8% avg upside 22 analysts	$75.00 115.84% Upside	-0.7%	·
RXRX Recursion Pharmaceuticals	Aug 05, 2026	BUY	Buy +141.0% avg upside 12 analysts	$8.00 143.24% Upside	+4.4%	·
GERN Geron	Aug 05, 2026	BUY	Strong Buy +169.7% avg upside 19 analysts	$4.00 154.71% Upside	-3.7%	·
NRIX Nurix Therapeutics	Aug 04, 2026	BUY	Strong Buy +22.8% avg upside 28 analysts	$34.00 27.59% Upside	+10.1%	·
CRSP Crispr Therapeutics AG	Aug 04, 2026	BUY	Buy +40.0% avg upside 41 analysts	$82.00 51.91% Upside	+1.7%	·
CELC Celcuity	Jul 15, 2026	BUY	Strong Buy +36.7% avg upside 16 analysts	$157.00 70.54% Upside	-5.4%	·
FATE Fate Therapeutics	Jul 10, 2026	HOLD	Buy +341.7% avg upside 31 analysts	—	-18.7%	·
STTK Shattuck Labs	Nov 07, 2025	HOLD	Strong Buy +192.5% avg upside 15 analysts	—	+278.3%	·
NBP NovaBridge Biosciences	Oct 24, 2025	HOLD	Strong Buy +1046.9% avg upside 14 analysts	—	-58.5%	·
NXTC NextCure	Dec 27, 2024	HOLD	Buy +148.3% avg upside 10 analysts	—	+29.8%	·
GB:0DPB Bavarian Nordic AS	Feb 16, 2023	BUY	Strong Buy +97.6% avg upside 5 analysts	$371.00 105.29% Upside	-30.3%	·
TECX Tectonic Therapeutic	Dec 07, 2022	BUY	Strong Buy +59.4% avg upside 24 analysts	$6.00 83.80% Downside	+78.2%	·
SYRE Spyre Therapeutics	Aug 25, 2022	HOLD	Strong Buy -9.7% avg upside 23 analysts	—	+0.0%	·
ATHXQ Athersys	Jun 03, 2022	HOLD	Buy +2996428471.5% avg upside 8 analysts	—	·	·
GNCAQ Genocea Biosciences	Apr 06, 2022	BUY	Strong Buy +573999900.0% avg upside 10 analysts	$6.00 599999900.06% Upside	·	·

🔒 23 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Gil Blum — Frequently Asked Questions

How accurate are Gil Blum's stock ratings?

Based on the calls 13Foresight could measure, about 54% of Gil's ratings were profitable over a one-year hold, with an average return of +8.5% per rating, or +5.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Gil ranked on 13Foresight?

Gil Blum is currently ranked #1063 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Gil cover?

Gil most recently has ratings on ABSI, TCRX, TSHA, MREO, RCKT, NKTX, AUTL, IMMX, LYEL, ARTV, SLDB, SRPT and 16 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Gil Blum

Rating Distribution

Welcome to 13Foresight!